Lead Product(s): BND-22
Therapeutic Area: Oncology Product Name: BND-22
Highest Development Status: IND Enabling Product Type: Large molecule
Deal Size: $1,125.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 12, 2021
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.